西达本胺 | 1883690-47-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 西达本胺
• 英文名称: Chidamide
• 英文别名: N-(2-amino-5-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
• CAS: 1883690-47-8
• 化学式: C₂₂H₁₉FN₄O₂
• 分子量: 390.4
• InChiKey: WXHHICFWKXDFOW-BJMVGYQFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  97.1
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES<br/>[FR] CONJUGUÉS D'ANTICORPS COMPRENANT UN AGONISTE DU RÉCEPTEUR DE TYPE TOLL ET POLYTHÉRAPIES
  申请人：NOVARTIS AG

  公开号：WO2018198091A1

  公开（公告）日：2018-11-01

  Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies. In some embodiments, the conjugates are used in combination with a second therapeutic agent.

  本文提供了包含Toll样受体激动剂的抗体偶联物，以及利用这些偶联物治疗癌症的用途。在某些实施例中，这些偶联物包括抗HER2抗体。在某些实施例中，这些偶联物与第二治疗剂联合使用。
• [EN] ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST<br/>[FR] CONJUGUÉS D'ANTICORPS COMPRENANT UN AGONISTE DU RÉCEPTEUR DE TYPE TOLL
  申请人：NOVARTIS AG

  公开号：WO2017072662A1

  公开（公告）日：2017-05-04

  Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

  本文提供了包含Toll样受体激动剂的抗体偶联物，以及利用这些偶联物治疗癌症的用途。在某些实施例中，这些偶联物包括抗HER2抗体。
• NOVEL HISTONE DEACETYLASE INHIBITORS
  申请人：Rajagopal Sridharan

  公开号：US20100222379A1

  公开（公告）日：2010-09-02

  Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds can inhibit HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as WO 2009/047615 A2 malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc.

  本文提供了一种新型的类荧光素化合物，其通式为(I)，以及它们的衍生物、类似物、互变异构体、立体异构体、多晶形、水合物、代谢产物、前药、溶剂化物、药学上可接受的盐和组合物。这些化合物可以抑制HDACs，并且可用作治疗或改善细胞生长相关疾病的治疗剂，例如恶性肿瘤、自身免疫疾病、皮肤病、感染、炎症等。
• Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
  申请人：——

  公开号：US20040224991A1

  公开（公告）日：2004-11-11

  The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis. 1

  本发明涉及一种新的苯甲酰胺衍生物的制备和药用，这些衍生物在规范式(I)中定义为组蛋白去乙酰化酶抑制剂(HDACI)，它们的制备方法以及使用这些化合物或其药学上可接受的盐治疗细胞增殖性疾病，例如癌症和银屑病。1
• Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation acivity
  申请人：Shenzhen Chipscreen Biosciences Ltd.

  公开号：EP2860174A2

  公开（公告）日：2015-04-15

  The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis.

  本发明涉及作为组蛋白去乙酰化酶抑制剂(HDACI)的式(I)说明书中所定义的新型苯甲酰胺衍生物的制备和药物用途、其制剂以及使用这些化合物或其药学上可接受的盐治疗细胞增殖性疾病（如癌症和牛皮癣）的方法。